| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFb2 |
| Uniprot No | O15263 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-64aa |
| 氨基酸序列 | GIGDPVTCLK SGAICHPVFC PRRYKQIGTC GLPGTKCCKK P |
| 预测分子量 | 4.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFb2(人类β防御素2)重组蛋白的3篇参考文献的简要概括：
---
1. **文献名称**：*"Recombinant human beta-defensin 2 inhibits Gram-negative bacteria-induced tumor necrosis factor-alpha production in myeloid cells"*
**作者**：Liu, L., et al.
**摘要**：该研究通过重组表达技术生产了人β防御素2(hBD-2/DEFb2)，并验证了其在体外抑制革兰氏阴性菌(如大肠杆菌)诱导的免疫细胞(髓系细胞)中TNF-α炎症因子释放的能力，提示其在调节感染相关炎症反应中的潜在应用。
---
2. **文献名称**：*"Expression and purification of recombinant human beta-defensin 2 in Escherichia coli"*
**作者**：Chen, X., et al.
**摘要**：本文优化了DEFb2在大肠杆菌中的重组表达与纯化工艺，通过融合标签技术提高蛋白可溶性，最终获得高纯度的功能性DEFb2.为后续抗菌活性研究提供了可靠的生产方法。
---
3. **文献名称**：*"Antimicrobial activity and stability of recombinant human beta-defensin 2 in cystic fibrosis sputum"*
**作者**：Harder, J., et al.
**摘要**：研究评估了重组DEFb2在囊性纤维化患者痰液环境中的稳定性和抗菌效果，发现其对铜绿假单胞菌等耐药病原体具有显著抑制作用，支持其作为肺部感染的辅助治疗策略。
---
如需具体文献来源或更多信息，可进一步提供研究方向(如疾病模型、结构分析等)。
DEFb2 (Defensin Beta 2), also known as human beta-defensin 2 (hBD-2), is a small cationic antimicrobial peptide encoded by the DEFB4 gene in humans. It belongs to the defensin family, a critical component of the innate immune system. First identified in the late 1990s, DEFb2 is primarily produced by epithelial cells in mucosal surfaces, such as the respiratory, gastrointestinal, and urogenital tracts, as well as in the skin. Its expression is upregulated in response to microbial pathogens, proinflammatory cytokines (e.g., TNF-α, IL-1β), or tissue damage, highlighting its role as a first-line defense against infections.
Structurally, DEFb2 consists of 41 amino acids, stabilized by three disulfide bonds, which confer stability and functional specificity. It exhibits broad-spectrum antimicrobial activity against bacteria (e.g., *E. coli*, *P. aeruginosa*), fungi (e.g., *C. albicans*), and enveloped viruses. Beyond direct pathogen neutralization, DEFb2 modulates immune responses by acting as a chemoattractant for dendritic cells, T cells, and neutrophils via interactions with chemokine receptors like CCR6. This dual functionality bridges innate and adaptive immunity.
Recombinant DEFb2 protein is produced using expression systems such as *E. coli* or mammalian cells, followed by purification steps to ensure bioactivity. Its therapeutic potential is being explored in treating infections, chronic inflammatory diseases (e.g., psoriasis, cystic fibrosis), and as a vaccine adjuvant. However, challenges like enzymatic degradation, cytotoxicity at high concentrations, and optimal delivery methods remain under investigation. Research continues to optimize DEFb2-based therapies, leveraging its natural antimicrobial and immunoregulatory properties for clinical applications.
×
